Neutrophilic dermatosis: disease mechanism and treatment.
PURPOSE OF REVIEW: The purpose of this review is to describe the physiopathological and therapeutic aspects of neutrophilic dermatosis, taking into account their most frequent associated conditions. RECENT FINDINGS: In autoinflammatory syndromes featuring neutrophilic dermatosis, the role of interle...
| Publicado en: | Current Opinion in Hematology Vol. 22; no. 1; pp. 23 - 30 |
|---|---|
| Autores principales: | , , |
| Formato: | review Journal Article |
| Publicado: |
Lippincott Williams & Wilkins
Jan2015
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109769213&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 109769213 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10656251 GGQ jtl: Current Opinion in Hematology issn: 10656251 maglogo: N pubinfo: dt: Jan2015 vid: 22 iid: 1 pid: 433 pub: Lippincott Williams & Wilkins place: Baltimore, Maryland artinfo: ui: 109769213 2012826165 10.1097/MOH.0000000000000100 NLM25394310 109769213 ppf: 23 ppct: 7 formats: tig: atl: Neutrophilic dermatosis: disease mechanism and treatment. aug: au: Maalouf, Diane Battistella, Maxime Bouaziz, Jean-David sug: subj: Antirheumatic Agents Therapeutic Use Proteins Therapeutic Use Pyoderma Gangrenosum Drug Therapy Pyoderma Gangrenosum Etiology Pyoderma Gangrenosum Metabolism Pyoderma Gangrenosum Pathology Animals Hematologic Neoplasms Drug Therapy Hematologic Neoplasms Metabolism Hematologic Neoplasms Pathology Interleukin 1 Metabolism Multiple Myeloma Drug Therapy Multiple Myeloma Metabolism Multiple Myeloma Pathology Paraproteinemias Drug Therapy Paraproteinemias Metabolism Paraproteinemias Pathology Sweet's Syndrome Drug Therapy Sweet's Syndrome Etiology Sweet's Syndrome Metabolism Sweet's Syndrome Pathology Tumor Necrosis Factor Antagonists and Inhibitors Tumor Necrosis Factor Metabolism ab: PURPOSE OF REVIEW: The purpose of this review is to describe the physiopathological and therapeutic aspects of neutrophilic dermatosis, taking into account their most frequent associated conditions. RECENT FINDINGS: In autoinflammatory syndromes featuring neutrophilic dermatosis, the role of interleukin-1 and tumor necrosis factor (TNF)-[alpha] cytokines in the immunopathogenesis of neutrophilic dermatosis has supported their classification as autoinflammatory diseases. In malignancy-associated neutrophilic dermatosis, the role of the malignant clone in myeloid neoplasms and the role of the monoclonal gammopathy and/or of the malignant plasmocyte clone in myeloma have been underlined. SUMMARY: Recent insights into neutrophilic dermatosis' pathophysiology have encouraged the use of targeted biological therapies for their treatment. Although systemic glucocorticoids remain the mainstay of treatment for Sweet's syndrome and pyoderma gangrenosum, anti-TNF-[alpha] is becoming the preferred treatment when pyoderma gangrenosum is accompanied by inflammatory bowel disease or rheumatoid arthritis. Interleukin-1 receptor inhibitor anakinra is a promising therapeutic alternative for refractory Sweet's syndrome. pubtype: Academic Journal doctype: review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|